TY - JOUR
T1 - Mutations of the EGFR, K-ras, EML4–ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma
AU - Ohba, Taro
AU - Toyokawa, Gouji
AU - Osoegawa, Atsushi
AU - Hirai, Fumihiko
AU - Yamaguchi, Masafumi
AU - Taguchi, Ken ichi
AU - Seto, Takashi
AU - Takenoyama, Mitsuhiro
AU - Ichinose, Yukito
AU - Sugio, Kenji
N1 - Funding Information:
We thank Miss Yumiko Oshima for reviewing the patients’ charts. This study was supported in part by a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science, and a grant from the Uehara Memorial Foundation.
Publisher Copyright:
© 2015, Springer Japan.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background and purpose: The EGFR, K-ras, EML4–ALK, and BRAF genes are oncogenic drivers of lung adenocarcinoma. We conducted this study to analyze the mutations of these genes in stage I adenocarcinoma. Methods: The subjects of this retrospective study were 256 patients with resected stage I lung adenocarcinoma. We analyzed mutations of the EGFR, K-ras, and BRAF genes, and the EML4–ALK fusion gene. We also assessed disease-free survival (DFS) to evaluate the prognostic value and overall survival (OS) to evaluate the predictive value of treatment after recurrence. Results: Mutations of the EGFR, K-ras, EML4–ALK, and BRAF genes were detected in 120 (46.8 %), 14 (5.5 %), 6 (2.3 %), and 2 (0.8 %) of the 256 tumors. Two tumors had double mutations (0.8 %). The incidence of EGFR mutations was significantly higher in women than in men. The EML4–ALK fusion gene was detected only in younger patients. The DFS and OS of the K-ras mutant group were significantly worse than those of the EGFR mutant group, the EML4–ALK fusion gene group, and the wild-type group. Six of the seven patients with the EML4–ALK fusion gene are still alive without recurrent disease. Conclusions: In patients with stage I adenocarcinoma, mutation of the K-ras gene was a poor prognostic factor for recurrence. The presence of a mutation of the EGFR or EML4–ALK gene was not a prognostic factor.
AB - Background and purpose: The EGFR, K-ras, EML4–ALK, and BRAF genes are oncogenic drivers of lung adenocarcinoma. We conducted this study to analyze the mutations of these genes in stage I adenocarcinoma. Methods: The subjects of this retrospective study were 256 patients with resected stage I lung adenocarcinoma. We analyzed mutations of the EGFR, K-ras, and BRAF genes, and the EML4–ALK fusion gene. We also assessed disease-free survival (DFS) to evaluate the prognostic value and overall survival (OS) to evaluate the predictive value of treatment after recurrence. Results: Mutations of the EGFR, K-ras, EML4–ALK, and BRAF genes were detected in 120 (46.8 %), 14 (5.5 %), 6 (2.3 %), and 2 (0.8 %) of the 256 tumors. Two tumors had double mutations (0.8 %). The incidence of EGFR mutations was significantly higher in women than in men. The EML4–ALK fusion gene was detected only in younger patients. The DFS and OS of the K-ras mutant group were significantly worse than those of the EGFR mutant group, the EML4–ALK fusion gene group, and the wild-type group. Six of the seven patients with the EML4–ALK fusion gene are still alive without recurrent disease. Conclusions: In patients with stage I adenocarcinoma, mutation of the K-ras gene was a poor prognostic factor for recurrence. The presence of a mutation of the EGFR or EML4–ALK gene was not a prognostic factor.
UR - http://www.scopus.com/inward/record.url?scp=84952064432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952064432&partnerID=8YFLogxK
U2 - 10.1007/s00595-015-1295-z
DO - 10.1007/s00595-015-1295-z
M3 - Article
C2 - 26711128
AN - SCOPUS:84952064432
SN - 0941-1291
VL - 46
SP - 1091
EP - 1098
JO - Surgery today
JF - Surgery today
IS - 9
ER -